EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications

Tommaso Greco iD, Antonio Mascio, Chiara Comisi, Chiara Polichetti iD, Silvio Caravelli iD, Massimiliano Mosca, Nicola Mondanelli iD, Elisa Troiano iD, Giulio Maccauro, Carlo Perisano

International Journal of Molecular Sciences · 03.02.2023 · 24 (3) · 3014

DOI: 10.3390/ijms24033014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.02.2023. Verfasst von Tommaso Greco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedics and Trauma Surgery Unit, Department of Ageing, Neurosciences, Head-Neck and Orthopedics Sciences, Università Cattolica del Sacro Cuore, F…. Hauptthemen laut MEDLINE: Diabetic Foot, Bone Density Conservation Agents, Osteolysis, Diabetes Mellitus. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Charcot Foot (CF), part of a broader condition known as Charcot Neuro-Osteoarthropathy (CNO), is characterized by neuropathic arthropathy with a progressive alteration of the foot. CNO is one of the most devastating complications in patients with diabetes mellitus and peripheral neuropathy but can also be caused by neurological or infectious diseases. The pathogenesis is multifactorial; many studies have demonstrated the central role of inflammation and the Receptor Activator of NF-κB ligand (RANKL)-Receptor Activator of NF-κB (RANK)-Osteoprotegerin (OPG) pathway in the acute phase of the disease, resulting in the serum overexpression of RANKL. This overexpression and activation of this signal lead to increased osteoclast activity and osteolysis, which is a prelude to bone destruction. The aim of this narrative review is to analyze this signaling pathway in bone remodeling, and in CF in particular, to highlight its clinical aspects and possible therapeutic implications of targeting drugs at different levels of the pathway. Drugs that act at different levels in this pathway are anti-RANKL monoclonal antibodies (Denosumab), bisphosphonates (BP), and calcitonin. The literature review showed encouraging data on treatment with Denosumab, although in a few studies and in small sample sizes. In contrast, BPs have been re-evaluated in recent years in relation to the high possibility of side effects, while calcitonin has shown little efficacy on CNO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic FootBone Density Conservation AgentsOsteolysisDiabetes MellitusHumansOsteoprotegerinReceptor Activator of Nuclear Factor-kappa BCalcitoninDenosumabNF-kappa BRANK Ligand

Stichwörter der Autor:innen

OPGRANKLbisphosphonatescalcitonincharcot footdenosumabdiabetes mellitusosteoarthopathy

Substanzen

OsteoprotegerinReceptor Activator of Nuclear Factor-kappa BCalcitoninDenosumabBone Density Conservation AgentsNF-kappa BRANK Ligand

Autor:innen und Institutionen

  • Orthopedics and Trauma Surgery Unit, Department of Ageing, Neurosciences, Head-Neck and Orthopedics Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Ital…
  • U.O.C. II Clinic of Orthopaedics and Traumatology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
  • Department of Medicine Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.

ORCID-Profile: Tommaso Greco, Chiara Polichetti, Silvio Caravelli, Nicola Mondanelli, Elisa Troiano

Zitieren

APA

Greco, T., Mascio, A., Comisi, C., Polichetti, C., Caravelli, S., Mosca, M., Mondanelli, N., Troiano, E., Maccauro, G., & Perisano, C. (2023). RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. International Journal of Molecular Sciences, 24(3), 3014. https://doi.org/10.3390/ijms24033014

Vancouver

Greco T, Mascio A, Comisi C, Polichetti C, Caravelli S, Mosca M, et al. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. International Journal of Molecular Sciences. 2023;24(3):3014. doi:10.3390/ijms24033014

BibTeX
@article{Greco2023,
  author = {Greco, Tommaso and Mascio, Antonio and Comisi, Chiara and Polichetti, Chiara and Caravelli, Silvio and Mosca, Massimiliano and Mondanelli, Nicola and Troiano, Elisa and Maccauro, Giulio and Perisano, Carlo},
  title = {RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {3014},
  doi = {10.3390/ijms24033014}
}
Kostenlos starten →